(202) 688 0222
CME Coalition
  • Home
  • About
    • Members
    • Staff
    • FAQ
  • Issues
    • The Value of CME
    • COVID-19
    • Health Disparities
    • Quality Improvement CME
    • Shared Decision-Making
    • Open Payments
    • CME vs. Marketing
  • Resources
    • Webinars
    • Code of Conduct
    • Privacy Policies
  • Membership
    • What We Do
    • Prospectus
    • Join the Coalition
  • CME in the News
  • Contact

CME COALITION DISCUSSES IMPORTANCE OF PRESCRIBER EDUCATION AT FDA WORKSHOP

5/10/2017

 
On May 3 and 4, 2017, the Food and Drug Administration (FDA) convened a public workshop (agenda) examining “Training Health Care Providers on Pain Management and Safe Use of Opioid Analgesics.” Andy Rosenberg presented testimony on behalf of the CME Coalition, in which he spoke to the role of CME in opioid prescriber education. Among the key points made in Andy’s remarks, "FDA should continue to rely on accredited CME as a vital tool in prescriber education in the opioid space. The strength of CME is that it can produce myriad educational activities that are targeted to physicians based on their professional practice gaps, individualized needs, and stages of learning and change. Added flexibility will allow prescriber education to better address individual prescribers’ educational and practice needs... Finally, as an incentive for prescribers to participate in opioid REMS, we recommend that the FDA encourage CMS to include opioid REMS as an improvement activity in the Quality Payment Program MIPS.”
CME Coalition Remarks to FDA May 2017.pdf
File Size: 315 kb
File Type: pdf
Download File


Comments are closed.

About

Mission
Government Affairs
Issues
Members
Staff
FAQ

Membership

Why Join
Testimonials
Join the Coalition

Resources

Sunshine Act
REMS
Commercial Logo Use
Privacy Policies
Code of Conduct

Newsroom

Press Releases
CME in the News
Blog
Picture
Copyright © 2014 CME Coalition | 1720 Eye St. NW, Washington DC | clamond@thornrun.com